Creating a World-Class Cancer Care Environment

Keimyung University Dongsan Medical Center Signs Contract to 

Introduce Korea’s First Synchrotron-Based Proton Therapy System

On July 16, Keimyung University Dongsan Medical Center (President & CEO: Chi-Heum Cho) hosted a signing ceremony at Dongsan Hospital’s Haengso Grand Auditorium to officially introduce a next-generation precision cancer treatment system — the Proton Therapy System.

This agreement, concluded about 470 days after the initial project briefing in March 2024, makes Dongsan Medical Center the first tertiary hospital in Korea to adopt a synchrotron-based proton therapy system, the ProTom Radiance 330. This advanced system has been clinically validated at Massachusetts General Hospital (MGH), a Harvard Medical School teaching hospital and one of the world’s leading cancer treatment institutions.

“Today’s event goes beyond a contract signing. 

It is the start of a shared vision and passion for the future of cancer care.

Through close collaboration, we aim to successfully implement 

the proton therapy system and create a treatment environment 

competitive on the global stage.”
- Paul Tso, CEO of ProTom International -

Combining synchrotron accelerator technology with Pencil Beam Scanning (PBS), the new system delivers radiation with unparalleled precision, targeting tumors according to their size, shape, and location while minimizing damage to surrounding healthy tissues. Particularly effective for complex and sensitive cases such as head and neck cancers, spinal tumors, and pediatric cancers, it is expected to reduce side effects and significantly improve patients’ quality of life.

Installation will begin in April 2028, with first treatments scheduled for December 2029. Once operational, Dongsan Medical Center will become Korea’s third proton therapy center after the National Cancer Center and Samsung Medical Center and the first outside the capital region.

“Introducing the proton therapy system is a major step 

toward balancing Korea’s advanced medical resources. 

It will allow regional patients to receive world-class 

cancer treatment without the need to travel to Seoul. 

We will continue expanding future-oriented healthcare infrastructure 

that brings real benefits to our community.”

- Chi-Heum Cho, President & CEO of KUDMC -

Around 100 guests attended the ceremony, including President & CEO Chi-Heum Cho, hospital leadership, Paul Tso, CEO of ProTom International, and Seong-Bae Jeon, CEO of MediNRod. 

The event included progress reports, the signing of the contract, and commemorative photography.